From £6.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Physiomics – “ongoing squeeze in biotech funding”. Uh oh...

By Steve Moore | Tuesday 4 April 2023


Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


Previously writing on drug development consultancy Physiomics (PYC), in October with the shares up to 2.6p I noted again a “Contract Award”, again attempted ramptastic… my view remains caveat emptor, Avoid. The shares last closed at 3.75p but are currently more than 25% lower today on the back of a “Trading and Company Update” announcement. So what’s the news?

You must be a registered member to read this story
ShareProphets is reader-supported journalism

Join us for free and gain access to three articles per month

Or become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

 

VANL

Van Elle Holdings – a Buy?

Thursday »

CCT

Character Group – a Buy?

 

ING

Ingenta – now a Buy again?

 

Clown

Which PR genius wrote this?

 

HAT

H&T Group – now again a Buy

Time left: 09:13:45